Breast Cancer

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Hypofractionated Regional Nodal Irradiation in Breast Cancer [NA]

  Clinical trial update for a study on hypofractionated regional nodal irradiation in breast cancer; the trial is currently not recruiting.

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients

  Clinical trial evaluating the impact of physical activity on outcomes in early-stage hormone receptor-positive breast cancer; currently recr…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer [NA]

  A clinical trial update describing a study to evaluate how alternative and complementary therapies affect adherence in patients treated with…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer [Phase 2]

  Phase 2 multicohort trial evaluating toripalimab in combination with investigator-selected chemotherapy for advanced HER2-negative breast ca…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: LiveWell mBC Pilot RCT [NA]

  The update describes a LiveWell metastatic breast cancer pilot randomized trial. It is currently not yet recruiting.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

  A non-interventional study sponsored by Novartis is evaluating the effectiveness and safety of ribociclib as adjuvant therapy for HR-positiv…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) [Phase 3]

  A Phase 3 trial (CAPItello-292) evaluating capivasertib in combination with a CDK4/6 inhibitor and fulvestrant for advanced/metastatic HR+/H…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: The Comparison Between M-E-BCS and C-O-BCS. [NA]

  This entry notes a planned clinical trial comparing two breast-conserving surgery approaches (M-E-BCS and C-O-BCS) for breast cancer. Recrui…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) [Phase 3]

  Clinical trial update: phase 3 study of tersolisib (LY4064809/STX-478) in combination with other anti-cancer therapies for advanced breast c…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer [Phase 1, Phase 2]

  A Phase 1/2 clinical trial to determine the optimal dose of BNT323 in combination with BNT327 for advanced breast cancer, currently recruiti…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]

  Novartis' ECI830 is being studied as a single agent or in combination in adults with advanced HR+/HER2- breast cancer and other advanced sol…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: The PREDICT Registry:

  A PREDICT Registry study sponsored by PreludeDx is recruiting to collect data on ductal carcinoma in situ (Stage 0 breast cancer).

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer [Phase 2]

  Phase 2 trial evaluating high-dose radiation therapy with pembrolizumab and chemotherapy in PD-L1–positive metastatic triple-negative breast…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

  A Phase 2 trial is evaluating adding an individualized cancer vaccine to durvalumab, tremelimumab, and chemotherapy in patients with metasta…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors [Phase 1]

  Phase 1 trial evaluating orally administered MOMA-313 in adults with advanced or metastatic solid tumors; the study is currently active but …

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) [Phase 3]

  A Phase 3 study of sacituzumab govitecan (Sac-TMT, MK-2870) for breast cancer is currently recruiting. The trial includes patients with trip…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Factors Associated With Breast Cancer Risks and Outcomes

  A Memorial Sloan Kettering Cancer Center study examining factors associated with breast cancer risk and outcomes. The trial is currently rec…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity [Phase 2]

  A Phase 2 clinical trial from Tanta University is evaluating whether dapagliflozin can prevent doxorubicin-induced cardiotoxicity in breast …

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer [Phase 3]

  Phase 3 clinical study evaluating adjuvant therapy with TQB3616 plus endocrine therapy versus placebo plus endocrine therapy in breast cance…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial [Phase 2]

  Phase 2 clinical trial (DOROTHY) evaluating dose-reduced docetaxel with cyclophosphamide for vulnerable older women with Stage I-III HER2-ne…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET [Phase 2]

  This clinical trial update describes a Phase 2 study evaluating detection and outcomes using novel F-18 FAP PET imaging in metastatic invasi…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Study of LY4337713 in Participants With FAP-Positive Solid Tumors [Phase 1]

  A Phase 1 clinical trial update for LY4337713 in participants with FAP-positive solid tumors; the study is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients [Phase 3]

  A Phase 3 clinical trial called ECLECTIC, evaluating EstroTEP and circulating biomarkers for ER-positive, HER2-negative metastatic breast ca…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors [Phase 2]

  A Phase 2 clinical trial (EPIC) evaluating enhanced pain coping strategies to manage treatment-related joint pain in breast cancer survivors…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer [Phase 1]

  Phase 1 clinical trial update for CF33-hNIS-antiPDL1 in metastatic triple-negative breast cancer shows the study is currently ACTIVE_NOT_REC…